Sarcopenia impacts on short- and long-term results of hepatectomy for hepatocellular carcinoma

Annals of Surgery

Volumn 261, Issue 6, 2015, Pages 1173-1183

  Voron, Thibault ^a,b   Tselikas, Lambros ^a,b   Pietrasz, Daniel ^a,b   Pigneur, Frederic ^a,b   Laurent, Alexis ^a,b   Compagnon, Philippe ^a,b   Salloum, Chady ^a,b   Luciani, Alain ^a,b,c   Azoulay, Daniel ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c INSERM U955   (France)

Author keywords

Analytic morphomics; Frailty; Hepatocellular Carcinoma; Sarcopenia; Surgical outcomes

Indexed keywords

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; SARCOPENIA; AGED; CARCINOMA, HEPATOCELLULAR; COMORBIDITY; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATIENT SELECTION; PREVALENCE; PROGNOSIS; RADIOGRAPHY; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; CARCINOMA, HEPATOCELLULAR; COMORBIDITY; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; SARCOPENIA; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84946197439     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000743     Document Type: Article

References (64)

1. Bray F, Ren J-S, Masuyer E, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133-1145.
2. Jemal A, Bray F, Center M. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
3. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485-1491.
4. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis. 2010;30:3-16.
5. Alazawi W, Cunningham M, Dearden J, et al. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther. 2010;32:344-355.
6. El-Serag HB, Marrero JA, Rudolph L, et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752-1763.
7. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255.
8. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918-928.
9. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology. 2000;31:840-845.
10. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003;38:207-215.
11. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-338.
12. Forner A, Reig ME, de Lope CR, et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30: 61-74.
13. Kruizenga H. Screening of nutritional status in the Netherlands. Clin Nutr. 2003;22:147-152.
14. Spiekerman AM, Rudolph RA, Bernstein LH. Determination of malnutrition in hospitalized patients with the use of a group-based reference. Arch Pathol Lab Med. 1993;117:184-186.
15. McWhirter J, Pennington C. Incidence and recognition of malnutrition in hospital J. P. McWhirter and C. R. Pennington. BMJ. 1994;308:945-948.
16. Corish CA, Kennedy NP. Protein-energy undernutrition in hospital in-patients (review). Br J Nutr. 2000;83:575-591.
17. Mann CD, Palser T, Briggs CD, et al. A review of factors predicting perioperative death and early outcome in hepatopancreaticobiliary cancer surgery. HPB (Oxford). 2010;12:380-388.
18. Isabel T. D, Correia M. The impact of malnutrition on morbidity, mortality, length of hospital stay and costs evaluated through a multivariate model analysis. Clin Nutr. 2003;22:235-239.
19. Panis Y, Maggiori L, Caranhac G, et al. Mortality after colorectal cancer surgery: a French survey of more than 84,000 patients. Ann Surg. 2011;254:738-743; discussion 743-744.
20. Merli M, Riggio O, Dally L. Does malnutrition affect survival in cirrhosis? Hepatology. 1996;15-20.
21. Peng S, Plank LD, McCall JL, et al. Body composition, muscle function, and energy expenditure in patients with liver cirrhosis: a comprehensive study. Am J Clin Nutr. 2007;85:1257-1266.
22. Alberino F, Gatta A, Amodio P, et al. Nutrition and survival in patients with liver cirrhosis. Nutrition. 2001;17:445-450.
23. Spiro A, Baldwin C, Patterson A, et al. The views and practice of oncologists towards nutritional support in patients receiving chemotherapy. Br J Cancer. 2006;95:431-434.
24. World Health Organization. Obesity and Overweight. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed May 15, 2014.
25. Tao W, Lagergren J. Clinical management of obese patients with cancer. Nat Rev Clin Oncol. 2013;10:519-533.
26. Figueiredo FA, Dickson ER, Pasha TM, et al. Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end-stage liver disease. Liver Transpl. 2000;6:575-581.
27. Prado CMM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629-635.
28. Baracos V. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr. 2010;91:1133-1137.
29. Sheetz KH, Zhao L, Holcombe SA, et al. Decreased core muscle size is associated with worse patient survival following esophagectomy for cancer. Dis Esophagus. 2013;26:716-722.
30. Montano-Loza AJ, Meza-Junco J, Prado CMM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10:166-173, 173.e1.
31. Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One. 2012;7:e37563.
32. Englesbe M, Patel S, He K. Sarcopenia and post-liver transplant mortality. J Am Coll Surg. 2010;211:271-278.
33. Tandon P, Ney M, Irwin I, et al. Severe muscle depletion in patients on the liver transplant wait list-its prevalence and independent prognostic value. Liver Transpl. 2012;18:1209-1216.
34. Harimoto N, Shirabe K, Yamashita Y-I, et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg. 2013;100:1523-1530.
35. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489-495.
36. Bedossa P, Poynard T. METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996;24:289-293.
37. Dindo D, Demartines N, Clavien P-A. Classification of surgical complications. Ann Surg. 2004;240:205-213.
38. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Geneva, Switzerland: World Health Organization; 2000.
39. Mourtzakis M, Prado CMM, Lieffers JR, et al. Apractical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997-1006.
40. Heymsfield SB, Wang Z, Baumgartner RN, et al. Human body composition: advances in models and methods. Annu Rev Nutr. 1997;17:527-558.
41. Lieffers JR, Bathe OF, Fassbender K, et al. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer. 2012;107:931-936.
42. Van Vledder MG, Levolger S, Ayez N, et al. Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg. 2012;99:550-557.
43. Peng PD, van Vledder MG, Tsai S, et al. Sarcopenia negatively impacts shortterm outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford). 2011;13:439-446.
44. Vitale A, Saracino E, Boccagni P, et al. Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. Transplant Proc. 2009;41:1260-1263.
45. Hsu C-Y, Lee Y-H, Hsia C-Y, et al. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology. 2013;57:112-119.
46. Englesbe MJ, Lee JS, He K, et al. Analytic morphomics, core muscle size, and surgical outcomes. Ann Surg. 2012;256:255-261.
47. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146-M156.
48. Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31:1539-1547.
49. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002;35:105-109.
50. Siegel AB, Lim EA, Wang S, et al. Diabetes, body mass index, and outcomes in hepatocellular carcinoma patients undergoing liver transplantation. Transplantation. 2012;94:539-543.
51. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, et al. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol. 1998;85:115-122.
52. Englesbe MJ, Terjimanian MN, Lee JS, et al. Morphometric age and surgical risk. J Am Coll Surg. 2013;216:976-985.
53. Tan BHL, Birdsell LA, Martin L, et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009;15:6973-6979.
54. Mir O, Coriat R, Dhooge M, et al. Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2. Anticancer Drugs. 2012;23:739-744.
55. Tan L-J, Liu S-L, Lei S-F, et al. Molecular genetic studies of gene identification for sarcopenia. Hum Genet. 2012;131:1-31.
56. Barillaro C, Liperoti R, Martone AM, et al. The new metabolic treatments for sarcopenia. Aging Clin Exp Res. 2013;25:119-127.
57. Morley JE, Argiles JM, Evans WJ, et al. Nutritional recommendations for the management of sarcopenia. J Am Med Dir Assoc. 2010;11:391-396.
58. Fang ST, Lo C-M, Lai E, et al. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med. 1994;331:1547-1552.
59. Strasser B, Steindorf K, Wiskemann J, et al. Impact of resistance training in cancer survivors: a meta-analysis. Med Sci Sports Exerc. 2013;45: 2080-2090.
60. Jones LW, Eves ND, Haykowsky M, et al. Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol. 2009;10: 598-605.
61. Sekine Y, Chiyo M, Iwata T, et al. Perioperative rehabilitation and physiotherapy for lung cancer patients with chronic obstructive pulmonary disease. Jpn J Thorac Cardiovasc Surg. 2005;53:237-243.
62. Benzo R, Wigle D, Novotny P, et al. Preoperative pulmonary rehabilitation before lung cancer resection: results from two randomized studies. Lung Cancer. 2011;74:441-445.
63. Mayo NE, Feldman L, Scott S, et al. Impact of preoperative change in physical function on postoperative recovery: argument supporting prehabilitation for colorectal surgery. Surgery. 2011;150:505-514.
64. Inoue J, Ono R, Makiura D, et al. Prevention of postoperative pulmonary complications through intensive preoperative respiratory rehabilitation in patients with esophageal cancer. Dis Esophagus. 2013;26: 68-74.